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a  b  s  t  r  a  c  t
Aims: The aim of the study was to determine the effect of hydrogen peroxide (HP) mouth-
wash on the incidence of ventilator associated pneumonia (VAP) in patients admitted to the
intensive care unit (ICU).
Methods: This was a randomized clinical trial conducted on 68 patients. The intervention
group used 3% HP as mouthwash and the control group used mouthwashes with 0.9% normal
saline (NS) twice a day. Data were collected using a questionnaire and the Modiﬁed Clinical
Pulmonary Infection Score (MCPIS). MCPIS includes ﬁve items, body temperature: white
blood cell count, pulmonary secretions, the ratio of pressure of arterial oxygen (PaO2) to
fraction of inspired oxygen (FiO2), and the chest X-ray. Each of these items scored 0–2. Scores
≥6 were considered as VAP signs. The SPSS-20 software was employed to analyze the data.
Results: In total, 14.7% patients of the HP group and 38.2% patients of the NS group contracted
VAP. The risk of VAP in the NS group was 2.60 times greater than that in the HP group
(RR  = 2.60, 95% CI: 1.04–6.49, p = 0.0279). The mean ± SD MCPIS was calculated as 3.91 ± 1.35
in  the HP group and 4.65 ± 1.55 in the NS group, a difference statistically signiﬁcant (p = 0.042).
There were no signiﬁcant differences in the risk factors for VAP between the two  groups.
Conclusion: HP mouthwash was found more effective than NS in reducing VAP. HP mouth-wash can therefore be used in routine nursing care for reducing VAP.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).∗ Corresponding author.
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ntroduction
osocomial pneumonia is the most common intensive care
nit (ICU) infection.1–3 Around 80–90% of patients with noso-
omial pneumonia are mechanically ventilated.4,5 Ventilator
ssociated pneumonia (VAP) is the inﬂammation of the lung
arenchyma caused by infection after the patient is connected
o the mechanical ventilator.6,7 Therefore, patients with VAP
ave a tracheal tube inserted or are under tracheostomy or
ight even be in the process of disconnecting from the ven-
ilator in the 48 h preceding the onset of symptoms.6,7 VAP
epresents a major public health issue in Asian countries
nd worldwide.8 The prevalence of VAP is 22.5% and 18.2%
n general and intensive surgical wards of the hospitals afﬁl-
ated to Tehran University of Medical Sciences in Iran,9 and
6.2% in China.10 VAP is one of the most common nosoco-
ial infections in Asian countries,11 caused by highly resistant
acterial,8 and a mortality rate ranging from 18.7% to 40.8%.11
ccess to appropriate antibiotic therapy for VAP is costly12;
oreover, Asian countries exhibit different patterns of epi-
emiology, etiology, and drug resistance proﬁle compared with
estern countries.13
The best way to prevent VAP is to use mouthwash.14
he American Association of Critical-Care Nurses (AACN)
2003) proposed mouthwash not only to bring comfort to the
atients, but also as a nursing care for the prevention of
AP.15,16 The AACN guideline recommends to brush the teeth
wice a day, swab the mouth every 2–4 h, and suction to clear
ecretions from the mouth.15 Oral rinsing with a solution,
el, and brush, or a combination of these along with aspi-
ation, reduces the risk of VAP in patients under ventilation.
revious studies that have aimed to assess the incidence of
AP have shown no difference between mouthwash and oral
are without brushing, with or without the use of mouthwash
olution.7 Although some institutions do not follow the AACN
ecommendations, it is actually oral care that helps preventing
AP.15 Using mouthwash in the patients is one of the main
esponsibilities of ICU nurses. However, despite the impor-
ance of using mouthwash for reducing VAP, its application
s often neglected or carelessly performed due to the criti-
al conditions of the patients and their severe physiological
eﬁciencies.15,16
Various solutions are used as mouthwash. Tap water might
e plentiful and economical; however, it is a source of nosoco-
ial infections and is therefore not recommended.16,17 The
pplication of NS is restricted due to the dry mouth and
atients intolerance.17 The long-term use of povidone–iodine
s a mouthwash solution at ICUs is also not recommended
ue to its absorption, modiﬁcations of the normal oral ﬂora
nd microbial resistance it may cause.18 Sodium bicarbon-
te solution is a mouthwash that softens the hardened
ucosa17 but causes greater bacterial plaque accumulation
ompared to chlorhexidine. Chlorhexidine is therefore consid-
red an anti-plaque agent with antimicrobial properties that
oes not lead to bacterial resistance in the oral cavity.1,17,18
ost of the evidence suggests that the use of chlorhexi-
ine is preferred for cardiac surgery patients; yet, its beneﬁts
n ICUs are unknown and its routine use is not recom-
ended for all ICU patients.15,17 The Society of Critical Care6;2 0(5):444–450 445
Medicine and the Centers for Disease Control and Preven-
tion have recommended the use of chlorhexidine mouthwash
for cardiac surgery patients and stated that its beneﬁts for
other patients are unknown.19 In addition, chlorhexidine
has certain side-effects, mainly including tooth discoloration,
bitter taste, impaired palate, mucosal damage, oral edema,
facilitating tartar build-up above the gum line, and unilateral
and bilateral parotid inﬂammation.20
HP is a colorless liquid with a strong oxidizing activity
that has been used as a tooth whitener and anti-plaque
agent for over 100 years. Through producing free radicals,
this solution has a killing effect on Gram-positive and Gram-
negative bacteria – particularly anaerobic bacteria. In addition
to its antibacterial properties, at 1.5–3% concentrations, it
effectively reduces gingival infections and dental plaque.20
The use of maximum 3% concentrations of HP as a mouth-
wash has been approved by the American Food and Drug
Administration.21 The most common side-effects of 3% and
lower concentrations of HP include temporary tooth sensitiv-
ity and gingival disorders, which are clinically negligible and
do not prohibit the use of HP as a mouthwash.22
During the past decade, a wealth of evidence have con-
ﬁrmed HP safety; today, many  oral hygiene centers use HP.22
In another review study, Berry et al. emphasized the need for
assessing the effect of HP in preventing VAP.17 Given there are
no deﬁnitive choice of solutions for this purpose, and consid-
ering that the effect of HP solutions has not been studied on
the incidence of VAP, and also given the high prevalence of
VAP in ICUs, the increasing medical costs associated with it,
its mortality rate and the substantial effect of mouthwash in
its prevention, conducting a study that seeks to ﬁnd an effec-
tive disinfectant solution for reducing VAP seemed essential.
The present study therefore aimed to determine the effect of
HP mouthwash on the incidence of VAP in ICU patients.
Type  of  study
Sixty-eight patients with endotracheal tube and mechanical
ventilation were enrolled in this randomized controlled clin-
ical trial, which was conducted at the medical and at the
surgical ICUs, between May 23rd and December 23rd, 2013.
The study inclusion criteria consisted of being over the age
of 18, having been under mechanical ventilation for over 48 h,
having had no more  than one intubation attempt, no facial or
oral trauma, no contra-indications to neither mouthwash use
nor to 30◦ bed head elevation, no history of HP allergies, and
no evidence suggesting VAP or aspiration. The study exclusion
criteria consisted of having had pneumonia prior to the begin-
ning of the study and in the ﬁrst 48 h of mechanical ventilation,
transfer from other departments and the elapse of 24 h since
the insertion of the tracheal tube, the removal of the tracheal
tube for any reason during the 5 days the study was being con-
ducted, and the patient’s death or transfer from the internal
unit to the surgery ICU and vice versa at any time during the
5 days of the study.
Those who met  the aforementioned criteria were selectedintervention group or the control group using block ran-
domization and after matching for age (maximum 5 years
difference), type of ICU (medical or surgery), and APACHE II
i s . 2 0446  b r a z j i n f e c t d 
scores (a score difference of 5).23 The requirement for conduct-
ing randomized controlled clinical practices with a minimal
variation in relation to the need for intensive care services
having at their disposal effective protocols for the effective
application of oral care and resulting reduction of nosocomial
pneumonia.24 Patients were randomly divided into two groups
by the use of a coin toss, where heads were assigned to the
intervention and tails to the control group.
Data  collection  instrument
The present study used a two-part questionnaire for data
collection. The ﬁrst part involved patients’ demographic infor-
mation, including age, gender, disease severity, occupation,
predisposing diseases, reason for admission, the depart-
ment referring the patient to the ICU, duration of hospital
stay, antibiotic use, antihistamine and anti-reﬂux medication,
gastroprokinetic agent and analgesic consumption, Glasgow
Coma Scale (GCS), history of smoking and drug abuse, which
were abstracted from the patient’s ﬁle and by questioning their
relatives. The second part involved the VAP diagnosis using the
MCPIS.
Pugin et al. proposed a score for the diagnosis of VAP
known as the Clinical Pulmonary Infection Score (CPIS).25
CPIS is based on both clinical and radiological signs, includ-
ing temperature, leucocytes count, massive purulent tracheal
secretions, chest X-ray, oxygenation (deﬁned as the ratio of
partial pressure of arterial oxygen and fraction of inspired
oxygen, PaO2/FiO2), and semi-quantitative cultures of tracheal
aspirate.26 Each diagnostic sign is scored on a scale of 0–2
points, with 12 being the maximum score and >6 indicating
VAP. This score has 93% sensitivity and 100% speciﬁcity for the
detection of VAP.25 Although Singh et al. introduced a modiﬁed
CPIS index (MCPIS) by omitting the secretion culture variable,
it still represents a valid method for the clinical diagnosis of
VAP.27 This index was validated by the American Thoracic
Society and the Infectious Disease Society of America.26 The
maximum score of MCPIS is 10, with <6 indicating the absence
of VAP.28 The MCPIS score of <6 improved the predictive value
(area under the curve of 0.89, 81.3% sensitivity, and 86.5%
speciﬁcity).29
The MCPIS, which examined ﬁve items, including body
temperature, white blood cell count, pulmonary secretions,
the ratio of pressure of arterial oxygen (PaO2) to fraction of
inspired oxygen (FiO2), and the chest X-ray. Each patient was
given  a score of 0–2 for each of these items based on his
conditions with 0 indicating normal conditions and 1 and 2
indicating worse and worst conditions, in respective order.
A body temperature of 36.5–38.4 ◦C was given the score of
0, 38.5–39 ◦C the score of 1, and temperatures in excess of
39 ◦C the score of 2. White blood cell counts between 4 and
11 thousand were given the score of 0, 11–17 thousand the
score of 1, and greater than 17 thousand the score of 2. Nor-
mal  pulmonary secretions were given the score of 0, and if
they exceeded the normal amount, they were given the score
of 1 or 2 based on the amount of secretion and the physi-
cian’s opinion. The PaO2/FiO2 ratio was calculated based on
the arterial gases and oxygen percentage set on the mechani-
cal ventilator. Ratios in excess of 200 were given the score of 0
and those lower than 200 the score of 2. The chest X-ray was 1 6;2  0(5):444–450
examined by a pulmonary specialist; if no problems were rec-
ognized, the patient received the score of 0, if scattered spots
were observed, the score of 1, and if concentrated spots were
observed the score of 2. The scores obtained for these ﬁve
items were added up; aggregate scores below 6 signiﬁed the
absence of a pneumonia diagnosis and aggregate scores equal
to or greater than 6 signiﬁed VAP.16,25
Scientiﬁc  validity  and  reliability  of  the  data  collection
instruments
Validity of the Modiﬁed Pulmonary Infection Scale was con-
ﬁrmed using the content validity method and a similar
study,16 and its reliability was conﬁrmed on 20 study subjects
with the Cronbach’s alpha of 0.83. Scores in excess of 6 for the
scale were reported as indicating the diagnosis of pneumo-
nia with the sensitivity of 93% and the speciﬁcity of 100% and
the correlation of 0.8 between the CPIS and secretion culture
yielded by bronchoalveolar lavage.30 Singh et al. eliminated
the culture and staining steps from the tracheal secretions as
it took 2–3 days to produce results and instead proposed the
modiﬁed CPIS.27 Many studies consider scores of 6 and above
in the scale to be appropriate diagnostic indicators of VAP.16,25
Methods
The ﬁrst mouthwash application was performed in the ﬁrst
24 h of admission. Conditions of using the mouthwash were
similar in both groups, and after washing their hands, the bed
head was elevated 30◦ in order to prevent aspiration of secret-
ions. After wearing sterile gloves, the patient’s oral mucosal
membrane, tongue and gingiva were washed using 4–6 cotton
swabs (depending on the patient’s oral health) soaked in 15
cc of 3% HP in the intervention group and in 0.9% NS in the
control group. Any excess discharges were collected through
suction pumps under similarly equal conditions. Before the
application of mouthwash and after elevating the bed head,
the tracheal tube and mouth secretions were suctioned out
using a green nelaton catheter size 14. The suction nozzle
was  replaced after each application of the mouthwash. This
procedure was repeated twice every day at 8am and 4pm.
As pouring NS solution into the tracheal tube contributes to
the incidence of pneumonia, it was arranged with the depart-
ment head nurse to avoid performing this unwanted mistake
and a note was afﬁxed to the patient’s bed. The tracheal tube
cuff was monitored before the application of mouthwash and
adjusted in pressure through a syringe if below the normal
levels, and the patient’s low tracheal tube cuff pressure was
recorded in the questionnaire. The tracheal tube cuff pres-
sure was measured by hand by the same nurse throughout the
study. The current guidelines do not recommend oral decon-
tamination but recommend the use of mouthwash solutions.
The ﬁrst researcher trained two nurses (one working in the
day shift and the other in the afternoon shift) to perform both
methods. The mouthwash solutions were prepared by the ﬁrst
researcher and provided to the nurses, who  were blinded to
their content. The doctor in charge of the patients diagnosed
with VAP was also blinded to the content of the mouthwash
solution. To provide the same quality of oral care to both
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roups, one nurse performed the mouthwash applications in
he morning and another nurse in the evening. The applica-
ion of these mouthwash formulas continued for ﬁve days.31
rior to the application of mouthwash study subjects were
xamined for pneumonia on days 1 and 5 using the MCPIS.
atients scoring below 6 on day 1 entered the study and those
coring greater than 6 on day 5 were diagnosed with VAP.





<40 2 5.9 
40–59 7 20.6 
60–79 16 47.1 
≥80 9 26.5 
Gender
Female 17 50.0 
Male 17 50.0 
Smoking
+ 12 35.3 
− 22 64.7 
ICU Unit
Internal 23 67.6 
Surgical 11 32.4 
Drug abuse
+ 5 14.7 
− 29 85.3 
Using analgesic
+ 8 23.5 
− 26 76.5 
Disease
Diabetes 2 6.3 
Gastrointestinal disease – – 
Hypertension 4 12.5 
Heart disease 4 12.5 
Lung disease 1 3.1 
Neurologic – – 
Multi disorders 16 43.7 
Without diseases 7 21.9 
Drug
Antihistamine 2 11 32.4 
Anti-reﬂux 4 11.8 
Antacids 28 82.4 
Antibiotics 29 85.3 
APACHEII
<17 15 44.1 
≥17 19 55.9 
Glasgow Coma Scale
<9 10 29.4 




c Fisher exact tests.6;2 0(5):444–450 447
Data  analysis
Statistical analyses were performed with SPSS 20.0 software
using the Kolmogorov–Smirnov, Mann–Whitney, chi-square,
and Fisher exact tests. Relative risk (RR) and 95% conﬁdence
interval (CI) were also calculated. p < 0.05 was considered as
statistically signiﬁcant.
e groups.
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Table 2 – Incidence of Ventilator associated pneumonia
(VAP) in hydrogen peroxide and normal saline groups.
Group Mouthwash
Hydrogen peroxide Normal saline
n % n %
VAP suffering 5 14.7 13 38.2
No-suffering 29 85.3 21 61.8
Total 34 100 34 100
Ethical  considerations
Ethical considerations of the study included obtaining per-
mission from the Ethics Committee (92.306537, 19.5.2013) and
Registry of Clinical Trials (IRCT201305236318N2), a letter of
introduction from the university research deputy and the con-
sent of the hospital and ICU authorities. Full explanations
were provided about the study objectives and methods, and
written consent was obtained from patients or their relatives
after ensuring them of the conﬁdentiality of their data and
their right to withdraw from the study.
Results
The mean ± standard deviation (SD) age of patients was
66 ± 15.5 in the HP group and 63.4 ± 20.5 in the NS group
(p = 0.563). The youngest patient was 19 years old and the old-
est 89. The majority (39.75%) of the patients were in the 60–79
age range and the minority (10.3%) were in the below 40 age
range; 50% of the patients in the HP group and 47.1% in the
NS group were male. There were no signiﬁcant differences
between the two groups in terms of gender (p = 0.808); 70.6%
of patients were hospitalized in the medical unit and 29.4% in
the surgery unit (p = 0.595).
The most frequent (50%) causes of hospitalization included
the loss of consciousness caused by strokes, cerebral bleed-
ing, and reaction to anesthetics, drug poisoning, Myasthenia
Gravis, and unknown causes. The highest APACHE II score was
observed in patients with loss of consciousness. The major-
ity of patients in the HP group (43.7%) and 38.3% in the NS
group suffered from multiple conditions; however, no sig-
niﬁcant differences were observed between the two groups
(p = 0.961). There was not any signiﬁcant difference between
the two groups of HP and NS in terms of type of ICU, pre-
disposing diseases, history of smoking, drug abuse, analgesic
drugs, antihistamines 2, anti-reﬂux, antacids and antibiotics,
APACHE II and GCS (Table 1).
14.7% of the patients in the HP group and 38.2% of the
patients in the NS group acquired VAP. The risk of VAP
in the NS group was 2.60 times higher than that in HP
group (RR = 2.60, 95% CI: 1.04–6.49, p = 0.0279) (Table 2). The
mean ± SD MCPIS was calculated as 3.91 ± 1.35 in the HP group
and 4.65 ± 1.55 in the NS group (p = 0.042).Discussion
The results obtained showed that the use of 3% HP mouthwash
signiﬁcantly reduced the incidence of VAP compared to the 1 6;2  0(5):444–450
use of NS mouthwash (RR = 2.60, 95% CI: 1.04–6.49, p = 0.0279).
The incidence rate of VAP was 14.7% in the HP group. Accord-
ing to a study, using a disinfectant mouthwash solution is the
best method for preventing VAP.14 In a study conducted by
Hutchins et al., HP was used as mouthwash solution along
with other VAP preventative measures. Although their study
was conducted without controls and the HP percentage was
not speciﬁed, the results showed an 89.7% reduction in the
incidence of VAP.32
In the present study, the incidence rate of VAP was 38.2% in
the NS group. In a study by Seguin et al. saline rinse was com-
pared to usual care (no wash) and found a decrease in VAP.33
Reeve reported that normal saline before tracheal suctioning
decreases the incidence of VAP.34 However, the evidence of the
effectiveness of normal saline rinsing as a mouthwash is not
strong enough. The tendency to cause dry mouth when rou-
tinely used as mouthwash has limited its use in critical care
units.35
Prevention of ventilator-associated events is a major task.36
Upgrading the oral hygiene in ICU patients may result in
reduced incidence of VAP. Although there are various oral care
measures for ICU patients proposed in the literature, one can-
not identify the most effective measures based on the avail-
able evidence.37 Standardization of oral care protocols in ICUs
is required in order to improve the quality of oral care provided
to ventilated patients.5 Although the use of mouthwash is the
best method for reducing VAP, using a disinfectant mouth-
wash solution is essential for reducing pneumonia. The HP
mouthwash examined in the present study has a killing effect
on oral anaerobic bacteria and by disinfecting the oral cavity it
prevents aspiration of secretions contaminated with bacteria
into the lower pulmonary tract, thus reducing VAP. However,
the NS solution does not have these properties. The oral health
care program have evidently improved oral mucosal health
and signiﬁcantly lowered the occurrence of VAP. The study
ﬁndings may serve as a pragmatic reference for health care
professionals involved in oral health care programs.
Bronchoalveolar lavage (BAL) is a reliable and deﬁnitive
method for the diagnosis of VAP, which, however, was not used
in the present study. It was also neither possible in the present
study to examine the mechanical ventilators’ system settings
nor assess the patients’ oral health. The results of the present
study indicate that use of HP mouthwash is more  effective
than NS mouthwash in reducing VAP, thereby encouraging
future studies to be conducted on the role of HP mouthwash
in the incidence of nosocomial pneumonia. It is also recom-
mended for future studies to compare HP to other mouthwash
solutions, especially in ICUs, in order to accomplish a more
evidence-based care.
Conclusion
HP mouthwash was more  effective than NS mouthwash in
reducing VAP. Nurses can use HP mouthwash in their routine
nursing care to reduce the incidence of VAP.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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